Compare Royal Caribbean Cruises Ltd (RCL) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Twist Bioscience Corp — how do they compare? Royal Caribbean Cruises Ltd trades at $261.61 (market cap $70.74B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 8.4× Twist Bioscience Corp's market cap, and Royal Caribbean Cruises Ltd pays a 2.27% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| RCL | TWST | |
|---|---|---|
Market Cap | $70.74B | $8.42B |
Sector | Consumer Cyclical | Health |
52-Week High | $350.23 | $153.10 |
52-Week Low | $246.71 | $24.16 |
Enterprise Value | $93.38B | $8.35B |
Dividend Yield | 2.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $264.5, down 0.26% on the day, with technical indicators showing a bearish trend near key support at $261. The company demonstrates strong fundamentals with Q2 2026 EPS beating expectations at $4.21 vs. $3.98, revenue growth to $17.93B in 2025, and robust profitability margins. Recent news highlights dividend declarations and institutional buying interest despite oil price concerns impacting cruise stocks.
The outlook remains positive with analyst consensus price target of $367.83 suggesting 39% upside, supported by earnings momentum and institutional accumulation. Key risks include oil price volatility affecting fuel costs and competitive pressures in the cruise industry. The stock presents a growth opportunity with solid fundamentals but requires monitoring of macroeconomic headwinds.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
